**Background**
Retinoic acid receptors (RARs) are nuclear receptors that mediate the biological effects of all-trans retinoic acid (atRA). The RAR family consists of three subtypes: RARα, RARβ, and RARγ. These receptors function as ligand-dependent transcription factors that regulate a wide array of physiological processes, including cell differentiation, proliferation, and apoptosis. Among these, RARβ is frequently downregulated or deleted in various types of cancer, and its reactivation has been shown to inhibit tumor growth and induce cell differentiation. Given the distinct roles of the three subtypes, the development of subtype-selective ligands is crucial to minimize off-target effects and maximize therapeutic efficacy. In this context, we will introduce a selective RARβ agonist – BMS641.
**Definition**
BMS641 (BMS-209641) is a selective RARβ agonist with a molecular weight of 414.92 and the chemical formula C27H23ClO2. According to the BMS641 technical information, this compound exhibits a high binding affinity for RARβ with a Kd value of 2.5 nM.
**In Vitro Studies**
The development of BMS641 was guided by the rational design based on the RARβ crystal structure. In terms of BMS641 biological activity, the compound demonstrates significant selectivity for the β-subtype over other RAR isoforms. Specifically, the affinity of BMS641 for RARβ is approximately 100 times higher than its affinity for RARα (Kd = 225 nM) or RARγ (Kd = 223 nM). These results indicate that BMS641 can selectively activate RARβ-mediated gene transcription without significantly affecting the pathways regulated by RARα or RARγ. In conclusion, BMS641 is a highly selective RARβ agonist that serves as a valuable tool for studying the specific roles of RARβ in cellular processes and cancer research.
Keywords
BMS641, 369364-50-1, BMS-209641, BMS 641, BMS-641, BMS209641, BMS 209641, RAR/RXR, Retinoic acid receptors, Retinoid X receptors, RARα, RARβ, RARγ, retinoic acid receptor, cancer progression
References